1. Home
  2. MBX vs NPCT Comparison

MBX vs NPCT Comparison

Compare MBX & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBX
  • NPCT
  • Stock Information
  • Founded
  • MBX 2018
  • NPCT 2020
  • Country
  • MBX United States
  • NPCT United States
  • Employees
  • MBX N/A
  • NPCT N/A
  • Industry
  • MBX
  • NPCT Investment Managers
  • Sector
  • MBX
  • NPCT Finance
  • Exchange
  • MBX NYSE
  • NPCT Nasdaq
  • Market Cap
  • MBX 381.4M
  • NPCT 316.0M
  • IPO Year
  • MBX 2024
  • NPCT N/A
  • Fundamental
  • Price
  • MBX $13.75
  • NPCT $10.93
  • Analyst Decision
  • MBX Strong Buy
  • NPCT
  • Analyst Count
  • MBX 6
  • NPCT 0
  • Target Price
  • MBX $37.50
  • NPCT N/A
  • AVG Volume (30 Days)
  • MBX 498.6K
  • NPCT 107.1K
  • Earning Date
  • MBX 08-16-2025
  • NPCT 01-01-0001
  • Dividend Yield
  • MBX N/A
  • NPCT 9.82%
  • EPS Growth
  • MBX N/A
  • NPCT N/A
  • EPS
  • MBX N/A
  • NPCT N/A
  • Revenue
  • MBX N/A
  • NPCT N/A
  • Revenue This Year
  • MBX N/A
  • NPCT N/A
  • Revenue Next Year
  • MBX N/A
  • NPCT N/A
  • P/E Ratio
  • MBX N/A
  • NPCT N/A
  • Revenue Growth
  • MBX N/A
  • NPCT N/A
  • 52 Week Low
  • MBX $4.81
  • NPCT $8.58
  • 52 Week High
  • MBX $27.50
  • NPCT $10.63
  • Technical
  • Relative Strength Index (RSI)
  • MBX N/A
  • NPCT 51.04
  • Support Level
  • MBX N/A
  • NPCT $10.76
  • Resistance Level
  • MBX N/A
  • NPCT $11.11
  • Average True Range (ATR)
  • MBX 0.00
  • NPCT 0.15
  • MACD
  • MBX 0.00
  • NPCT -0.02
  • Stochastic Oscillator
  • MBX 0.00
  • NPCT 52.56

About MBX MBX BIOSCIENCES INC

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest

Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.

Share on Social Networks: